Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -1.52 Increased by +32.44% | -1.69 Increased by +10.06% |
| May 2, 24 | -2.03 Increased by +12.88% | -1.73 Decreased by -17.34% |
| Feb 15, 24 | -1.52 Increased by +29.63% | -1.62 Increased by +6.17% |
| Nov 2, 23 | -2.23 Increased by +36.29% | -2.08 Decreased by -7.21% |
| Aug 3, 23 | -2.25 Increased by +0.44% | -2.07 Decreased by -8.70% |
| May 4, 23 | -2.33 Decreased by -6.39% | -1.98 Decreased by -17.68% |
| Feb 16, 23 | -2.16 Decreased by -20.67% | -2.14 Decreased by -0.93% |
| Nov 2, 22 | -3.50 Decreased by -224.07% | -1.81 Decreased by -93.37% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 139.49 M Increased by +42.27% | -133.52 M Increased by +16.37% | Decreased by -95.71% Increased by +41.21% |
| Jun 30, 24 | 147.03 M Increased by +35.75% | -131.60 M Increased by +17.66% | Decreased by -89.51% Increased by +39.34% |
| Mar 31, 24 | 108.83 M Increased by +8.30% | -170.68 M Decreased by -4.09% | Decreased by -156.83% Increased by +3.88% |
| Dec 31, 23 | 127.39 M Increased by +23.27% | -123.19 M Increased by +18.86% | Decreased by -96.70% Increased by +34.18% |
| Sep 30, 23 | 98.05 M Increased by +8.10% | -159.65 M Increased by +34.87% | Decreased by -162.82% Increased by +39.75% |
| Jun 30, 23 | 108.31 M Increased by +21.23% | -159.83 M Decreased by -1.05% | Decreased by -147.57% Increased by +16.64% |
| Mar 31, 23 | 100.50 M Increased by +25.72% | -163.97 M Decreased by -7.65% | Decreased by -163.16% Increased by +14.37% |
| Dec 31, 22 | 103.35 M Increased by +23.93% | -151.83 M Decreased by -23.99% | Decreased by -146.91% Decreased by -0.04% |